EGFR and non-small cell lung carcinoma: Diagnosing acquired resistance mechanisms to osimertinib therapy was performed for the first time in NSCLC patients with mutations in the EGFR gene and with resistance to first- or second-generation EGFR TKIs who received osimertinib in the further lane of treatment [16,17,19].